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SUMMARY
Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell 
acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. However, suboptimal clinical 
outcomes have been associated with decreased expansion and persistence of adoptively transferred 
CAR T cells, antigen-negative relapses, and impairment by an immunosuppressive tumor 
microenvironment. Improvements in CAR T cell design are required to enhance clinical efficacy, 
as well as broaden the applicability of this technology. Here, we demonstrate that interleukin-18 
(IL-18)-secreting CAR T cells exhibit enhanced in vivo expansion and persistence and 
significantly increase long-term survival in syngeneic mouse models of both hematological and 
solid malignancies. In addition, we demonstrate that IL-18-secreting CAR T cells are capable of 
modulating the tumor microenvironment, as well as enhancing an effective endogenous anti-tumor 
immune response. IL-18-secreting CART cells represent a promising strategy to enhance the 
clinical outcomes of adoptive T cell therapy.
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In Brief Avanzi et al. generate CAR T cells that secrete IL-18 and show improved activity in 
syngeneic hematologic and solid tumor models without prior preconditioning. They further show 
enhanced recruitment and anti-tumor activity of endogenous T cells.
INTRODUCTION
Adoptive T cell therapy with chimeric antigen receptor (CAR) T cells has emerged as an 
effective therapy for the treatment of B cell hematological malignancies, and several groups 
have published results utilizing anti-CD19 CAR T cells for the treatment of B cell acute 
lymphoblastic leukemia (B-ALL), and non-Hodgkin’s lymphoma (NHL) (Brentjens et al., 
2013; Davila et al., 2014; Lee et al., 2015; Maude et al., 2014). However, despite high rates 
of initial complete remissions, a considerable number of patients will relapse with either 
CD19+ or CD19− disease after CD19-targeted CAR T cell therapy (Gardner et al., 2016; 
Maude et al., 2014; O’Rourke et al., 2017). Relapses that retain surface CD19 expression are 
thought to result from decreased persistence and/or decreased function of CAR-modified T 
cells. Unsurprisingly, increased circulating CAR T cell persistence correlates with durable 
responses and enhanced clinical outcomes (Kalos et al., 2011; Maude et al., 2014). Relapses 
may also occur secondary to emergence of tumor cells that have lost CD19 expression, 
despite persistence of functional CAR T cells. The incidence of relapses with antigen loss is 
related to escape variants (Sotillo et al., 2015), and according to recent estimates, epitope 
loss accounts for up to 40% of reported relapses (Gardner et al., 2017; Maude et al., 2014; 
O’Rourke et al., 2017). In addition, CAR T cells have demonstrated limited efficacy for the 
treatment of other hematological malignancies, such as chronic lymphocytic leukemia 
(CLL), as well as solid tumor malignancies (Brown et al., 2016; Feng et al., 2017; Jackson et 
al., 2016; Louis et al., 2011; O’Rourke et al., 2017; Wang et al., 2015).
Emerging evidence suggests that an immunosuppressive tumor microenvironment may lead 
to early dysfunction, decreased expansion, and poor persistence of adoptively transferred T 
cells (Cherkassky et al., 2016; Gajewski et al., 2006; John et al., 2013). CAR T cells capable 
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of overcoming these limitations are needed in order to improve clinical outcomes, decrease 
relapses, and expand the spectrum of diseases treated with this technology.
Interleukin-18 (IL-18) is an IL-1 family cytokine produced by macrophages that directly 
stimulates interferon-γ (IFN-γ) secretion, and has pleiotropic effects on cells of the 
endogenous immune system. This property makes IL-18 a promising candidate for 
enhancing the anti-tumor efficacy of genetically modified T cells. In fact, IL-18-secreting 
CAR T cells have recently been shown to improve anti-tumor efficacy in a xenogeneic 
mouse model of CD19+ hematologic malignancies (Hu et al., 2017). However, due to the 
lack of an intact host immune system in these mice, the efficacy of this approach in the 
presence of an immunosuppressive tumor microenvironment remains unknown. In a more 
recent study, IL-18-secreting CAR T cells eradicated established pancreatic cancer and 
metastatic lung cancer in syngeneic and xenogeneic pre-clinical solid tumor models, 
respectively (Chmielewski and Abken, 2017).
In this study, we demonstrate that CAR T cells engineered to secrete IL-18 exhibit enhanced 
proliferation and persistence, and significantly increase long-term survival in syngeneic 
mouse models of both hematologic and metastatic solid tumor malignancies. We further 
demonstrate that this effect is largely dependent on autocrine IL-18 signaling. Finally, we 
show that IL-18 armored CAR T cells are capable of recruiting an effective and 
comprehensive endogenous anti-tumor immune response.
RESULTS
Human IL-18-Secreting CAR T Cells Display Enhanced Proliferation and Prolong Survival 
in a Xenograft Scid-Beige Mouse Model
We generated the human CD19-targeted 1928z-hIL18 CAR retroviral construct from a 
previously described and clinically utilized 1928z CAR construct (Brentjens et al., 2003). 
Ovarian tumor-targeted anti-Muc16ecto 4H1128z CAR T cells were utilized as untargeted 
controls (Figure 1A) (Chekmasova et al., 2010). The 1928z-hIL18 CAR showed comparable 
gene transfer to 1928z CARs (Figure S1A). Both 1928z-hIL18 and 1928z CAR T cells had 
similar CD4+ and CD8+ populations, with the majority of the transduced cells being CD8+ 
(Figure S1B). There were no differences in central/effector memory phenotypes between 
1928z-hIL18 and 1928z CAR T cells (Figure S1C). To validate the construct, human T cells 
modified to express the 1928z-hIL18 CAR vector were compared to 1928z CAR T cells and 
demonstrated enhanced in vitro IL-18 (p = 0.004), IFN-γ (p < 0.0001), and IL-2 (p = 
0.0003) secretion after stimulation with CD19+ NALM6 B-ALL tumor cells (Figure 1B). In 
addition, 1928z-hIL18 CAR T cells compared to 1928z CAR T cells demonstrated enhanced 
proliferation (Figure 1C) (p = 0.003) and retained anti-tumor cytotoxicity (Figures 1D and 
1E) after NALM6 tumor stimulation. No difference in markers associated with T cell 
dysfunction were observed between 1928z and 1928z-hIL18 CAR T cells in vitro on days 7 
and 14 (Figure S1G). Next, we examined the gene expression profile of both CAR T cells at 
day 1 and day 8 after co-culture with tumor cells using the nanoString PanCancer Immune 
Profiling Panel. Only genes with statistical significance are shown (p < 0.05). Overall, 
compared to 1928z, 1928z-hIL18 T cells exhibited increased expression of pro-
inflammatory and activation genes (IFN-γ and PD1) and decreased expression of pro-
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apoptotic genes (Pycard and ETS1) on day 1 after tumor stimulation (Figure 1F). After 8 
days of coculture, pro-inflammatory genes (MAPK8 and TNFαIP3) and genes indicative of 
a central memory phenotype (CCR7) were selectively upregulated in 1928z-hIL18 CAR T 
cells (Figure 1G), compared to 1928z CAR T cells. In order to assess the in vivo anti-tumor 
efficacy of 1928z-hIL18 CAR T cells, we treated NALM6-GFP+/Luc+ tumor-bearing Scid-
Beige mice with 1928z or 1928z-hIL18 CAR T cells. This tumor model has been previously 
demonstrated to be extremely aggressive and multiple second-generation 1928z CAR T cell 
injections were necessary to obtain long-term anti-tumor efficacy (Brentjens et al., 2007). 
Mice were inoculated with 1 × 106 NALM6-GFP+/Luc+ tumor cells on day 0 and treated 
with 5 × 106 CAR T cells on day 1. As demonstrated, 1928z-hIL18 CAR T cells 
significantly enhanced survival compared to 1928z (p = 0.0006) (Figure 1H) and 
significantly lowered tumor burden as assessed by bioluminescent imaging (region of 
interest [ROI]) (Figure 1I).
Murine IL-18-Secreting CAR T Cells Enhance Survival of EL4hCD19+ Tumor-Bearing 
Syngeneic Immunocompetent Mice in the Absence of Chemotherapy Preconditioning
Given that immunocompromised xenotransplant mouse tumor models have limited clinical 
and biological relevance, we next studied IL-18-secreting CAR T cells in the context of 
syngeneic, immune competent models of disease wherein a more comprehensive analysis of 
the anti-tumor effects mediated by murine IL-18 (mIL-18)-secreting T cells could be 
assessed. To this end, we generated a panel of retroviral vectors encoding murine CAR T 
cells that target hCD19: 19m28mz-mIL18, 19mz-mIL18, 19mDel-mIL18, and 19mDel all 
derived from a 19m28mz retroviral construct (Figure 2A). Murine 19m28mz-mIL18 showed 
comparable gene transfer to 19m28mz (Figure S1D). There were no differences in 
CD4/CD8 ratios (Figure S1E) or effector/central memory phenotypes (Figure S1F) between 
both groups. As predicted, mouse T cells modified with the 19m28mz-mIL18 retroviral 
vector demonstrated enhanced in vitro IL-18 secretion (p = 0.005) when cocultured with a 
thymoma tumor cell line (EL4), modified to express hCD19 (EL4hCD19+) (Figure 2B). 
19m28mz-mIL18 CAR T cells showed comparable expansion and anti-tumor cytotoxicity 
compared to 19m28mz CAR T cells (Figures S2A and S2B). Utilizing a syngeneic hCD19+ 
transgenic mouse model (C57BL/6 mCD19+/− hCD19+/−), we evaluated the efficacy of 
19m28mz-mIL18 CAR T cells in mice infused systemically with EL4hCD19+ tumor cells. 
We have previously shown that EL4hCD19+ tumor-bearing mice treated with anti-hCD19 
CAR T cells in the absence of prior cyclophosphamide preconditioning do not demonstrate 
tumor eradication and long-term survival (Pegram et al., 2012). In these experiments, CAR 
T cells failed to eradicate tumor cells and all mice succumbed to disease at early time points 
(Pegram et al., 2012). We used this aggressive tumor model to investigate whether 
19m28mz-mIL18 CAR T cells could overcome the lack of anti-tumor efficacy exhibited by 
second-generation 19m28mz T cells. In the absence of preconditioning, 19m28mz-mIL18 
CAR T cells (2.5 × 106 CAR cells/mouse) were capable of significantly enhancing long-
term survival of EL4hCD19+ tumor-bearing syngeneic mice, compared to 19m28mz CAR T 
cell treatment (p < 0.0001) (Figure 2C). Anti-tumor efficacy was readily evident even in the 
context of treatment with reduced 19m28mz-mIL18 CAR T cell dose (1.2 × 106 CAR cells/
mouse) (Figure 2D). Furthermore, 19m28mz-mIL18 CAR T cells were capable of enhancing 
long-term survival in a delayed tumor model wherein CAR T cells were administered on day 
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7 after tumor inoculation (p = 0.0009) (Figure 2E). We next assessed whether 19m28mz-
mIL18 CAR T cells persist and retain meaningful anti-tumor efficacy against tumor 
rechallenge. Surviving mice previously inoculated with 1 × 106 EL4hCD19+ tumor cells on 
day 0 and treated with 19m28mz-mIL18 CART cells on day 1 were re-challenged with a 
second injection of 1 × 106 tumor cells 40 days after the first tumor injection. Mice treated 
with 19m28mz-mIL18 CAR T cells were capable of rejecting a second lethal dose of tumor 
(p = 0.004) (Figure 2F). Significantly, mice that succumbed to disease in these studies 
harbored CD19+ tumor cells on necropsy.
Murine IL-18-Secreting CAR T Cells Exhibit Enhanced Expansion and Persistence and 
Induce Prolonged B Cell Aplasia Dependent on Autocrine IL-18R Signaling
19m28mz-mIL18 CART cells displayed enhanced in vivo expansion and were detected in 
peripheral blood by flow cytometry for up to 28 days after infusion, whereas 19m28mz CAR 
T cells were not detected in peripheral blood at any time point tested (Figure 3A). In vivo, 
19m28mz-mIL18 CAR T cells were predominantly CD8+ (Figure S3A), similar to increased 
CD8/CD4 ratios pre-infusion. We have previously demonstrated that hCD19+ transgenic 
mice develop B cell aplasia after treatment with CD19-directed CAR T cells (Pegram et al., 
2012). B cell aplasia in this mouse model is an effective surrogate marker for CD19 targeted 
CAR T cell activity and directly correlates with the presence of CAR T cells either in 
circulation or in the bone marrow (Pegram et al., 2012). Mice treated with 19m28mz-mIL18 
CAR T cells developed relative and persistent B cell aplasia for up to 150 days after 
treatment, whereas mice treated with 19m28mz CAR T cells did not develop B cell aplasia 
at any time point (Figure 3B). Untreated tumor-bearing mice had similar B cells compared 
to 19m28mz- treated mice (Figure S3B), likely due to the inability of 19m28mz T cells to 
expand in vivo without lymphodepleting therapy. These data further serve to highlight the 
potency of IL-18-modified CARs in a syngeneic model without preconditioning. To further 
verify the persistence of 19m28mz-mIL18 CAR T cells over time and to validate the role of 
these CAR T cells in observed prolonged B cell aplasia, bone marrow aspirates were 
collected from 19m28mz-mIL18- treated mice and assayed for the CAR construct by PCR. 
19m28mz-mIL18 CAR T cells were detected by PCR in the bone marrow at 35, 80, 120, and 
150 days after infusion (Figure 3C), suggesting that the prolonged B cell aplasia was directly 
related to the enhanced persistence of CAR T cells in the bone marrow. In addition, we 
found that 19m28mz-mIL18 CAR T cells were capable of significantly enhancing serum 
levels of IL-18, IFN-γ, and tumor necrosis factor α (TNFα) at day 7, compared to 
19m28mz CAR T cells (p = 0.0002, p < 0.0001, p = 0.005, respectively) (Figure 3D). These 
data provide a mechanistic basis for the rejection of a second round of tumor inoculation. 
Significantly, no increase in serum IL-6, a cytokine associated with cytokine release 
syndrome (CRS) in the clinical setting, was detected in mice treated with 19m28mz-mIL18 
CAR T cells (Figure 3D).
We initially utilized a second-generation CAR T cell containing a CD28 signaling domain in 
our experiments. To evaluate if “signal 2” (CD28 costimulation) was dispensable for IL-18 
armored CAR T cell anti-tumor efficacy and persistence, we engineered first-generation 
CAR T cells that lack the CD28 costimulatory signaling domain (19mz-mIL18) and directly 
compared these 19mz-mIL18 (signal 1+3) CAR T cells in vivo to second-generation 
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19m28mz-mIL18 CAR T cells (signal 1 + 2 + 3). First-generation 19mz-mIL18 CAR T cells 
were capable of inducing long-term survival; however, the overall survival benefit was 
inferior to that seen in mice treated with the second-generation 19m28mz-mIL18 CAR T 
cells (Figure 3E). In addition, 19mz-mIL18 CAR T cells demonstrated only modest 
expansion and induced only transient B cell aplasia in peripheral blood compared to mice 
treated with 19m28mz-mIL18 CAR T cells (Figures 3F and 3G).
Next, in order to determine whether the effects of 19m28mz-mIL18 CAR T cells were 
dependent on IL-18 secretion alone (signal 3), CAR-mediated T cell signaling (signal 1), or 
both concomitantly, we engineered constructs with deletion of the intracellular CD28 and 
CD3z signaling domains (19mDEL and 19mDEL-mIL18 CAR T cells). These T cells are 
capable of recognizing the tumor but do not display any signaling through the CAR and 
therefore no direct killing of the targeted tumor cells. Both 19mDEL and 19mDEL-mIL18 
CAR T cells failed to enhance survival in EL4hCD19+ tumor-bearing syngeneic mice 
(Figure S4A). Taken together, in this model, signals 1, 2, and 3 are required for optimal anti-
tumor efficacy. In order to determine whether the enhanced effect of IL-18-secreting CAR T 
cells was dependent on autocrine IL-18 stimulation, we compared the in vivo efficacy of 
19m28mz-mIL18–transduced CAR T cells derived from IL-18R knockout mice splenocytes 
(C57BL/6 IL-18R−/−) to 19m28mz-mIL18 CAR T cells derived from transgenic mice 
splenocytes (C57BL/6 mCD19+/− hCD19+/−). CAR T cells derived from IL-18R−/− 
splenocytes do not have any deficits in cytokine production or cytotoxicity at baseline 
(Figures S4B and S4C). Mice treated with 19m28mz- mIL18 CAR T cells derived from 
IL-18R knockout splenocytes failed to enhance long-term survival, expansion, persistence, 
or B cell aplasia (p = 0.001; p = 0.0003; p < 0.0001, respectively) (Figures 3H, 3I, and 3J). 
Furthermore, serum IFN-γ levels were significantly lower in mice treated with IL18R
−/−
 19m28mz-mIL18 CAR T cells (p < 0.0001) (Figure 3K).
To confirm that our findings were not restricted to CD19+ hematological malignancies, we 
expanded our studies to a metastatic ovarian cancer solid tumor model. We generated murine 
retroviral constructs of our previously published 4H11-targeting CAR to the truncated 
MUC16 antigen (MUC16ecto) (Chekmasova et al., 2010; Koneru et al., 2015) and conducted 
in vivo experiments. C57BL/6 syngeneic mice were inoculated with ID8 (MUC16ecto) 
ovarian tumor cells and treated with 4H11m28mz or 4H11m28mz-mIL18 CAR T cells. Our 
results demonstrated that 4H11m28mz-mIL18 CAR T cells were capable of significantly 
enhancing long-term survival in both low and high tumor burden models of syngeneic 
metastatic ovarian carcinoma (Figures S5A and S5B). These studies exemplify the potential 
application of this IL-18-secreting adoptive CAR T cell approach to both hematologic and 
solid tumor malignancies.
IL-18-Secreting CAR T Cells Modulate the Tumor Microenvironment
To assess the capacity of 19m28mz-mIL18 CAR T cells to migrate to the tumor site as well 
as their effects on endogenous immune cells, we performed experiments in 
immunocompetent syngeneic mice and utilized mass cytometry (cytometry by time of flight 
[CyTOF]) to analyze bone marrow samples. EL4 tumor cells have been shown to migrate to 
and proliferate in the bone marrow (Krevvata et al., 2014; Richards et al., 2006). CyTOF 
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results demonstrated that, unlike 19m28mz CAR T cells, 19m28mz-mIL18 CAR T cells 
were capable of migrating to the bone marrow and were detectable at day 18 after 
intravenous (i.v.) injection (Figure 4A). Bone marrow analysis demonstrated that 19m28mz-
mIL18 CAR T cells were indeed capable of not only significantly decreasing the B cell 
population (Figure 4B) but also of inducing expansion of bone marrow endogenous immune 
effector cells, such as natural killer (NK) cells, NKT cells, dendritic cells (DCs), and 
endogenous CD8 T cells, compared to 19m28mz CAR T cell-treated mice (p = 0.03; p = 
0.03; p = 0.03; p = 0.03; p = 0.03, respectively) (Figure 4B). The increased CD8 T cell 
population in the bone marrow was mostly composed of endogenous CD8 non-CAR T cells 
(Figure 4C). More interestingly, 19m28mz-mIL18 CAR T cells were capable of modulating 
and activating endogenous immune cells residing in the bone marrow. Mice treated with 
19m28mz-mIL18 CAR T cells, compared to mice treated with 19m28mz CAR T cells, 
displayed enhanced numbers of endogenous CD8 T cells with a central memory phenotype 
(CD44+; Ly6C+) (p = 0.01), macrophages with an M1 phenotype (MHC-II+) (p < 0.0001), 
and DCs with a more mature and activated phenotype (CD86+; MHC-II+) (p = 0.02) 
(Figures 4D–4F). Also, while many endogenous and CAR+ CD8 T cells exhibited 
characteristics of central memory cells (CD44+; Ly6C+), CAR T cells expressed higher 
levels of CD27, PD-1, and CD3 (Figure 4G).
IL-18-Secreting CAR T Cells Recruit Endogenous Anti-Tumor Immune Effector Cells and 
Broaden the Anti-Tumor Response Beyond the CAR Target
We postulated that 19m28mz-mIL18 CART cells could possibly be stimulating endogenous 
CD8T cells toward a central memory phenotype and thus enhancing the anti-tumor effect 
through recruitment of endogenous CAR− tumor targeted T cells. To evaluate this 
hypothesis, we inoculated syngeneic mice with a mixed population of equal amounts of 
EL4hCD19+ and EL4hCD19− tumor cells, followed by treatment with anti-CD19 19m28mz-
mIL18 CAR T cells. Interestingly, 19m28mz-mIL18 CAR T cells were capable of 
enhancing long-term survival of mice inoculated with both CD19+ and CD19− tumor cells at 
a 1:1 ratio (Figure 5A). This is consistent with recruitment of endogenous CD8 T cells 
targeted to antigens other than CD19 expressed by CD19− tumor cells. To further verify that 
19m28mz-mIL18 CAR T cells recruit endogenous tumor targeted T cells, we conducted 
additional enzyme-linked immunospot (ELISPOT) experiments with fluorescence-activated 
cell sorting (FACS)-sorted CD3+ CAR− splenocytes (Figure S6A) derived from EL4hCD19+ 
tumor-bearing mice treated with either 19m28mz or 19m28mz-mIL18 CART cells. 
ELISPOT results demonstrated that isolated CAR− splenocytes derived from mice treated 
with 19m28mz-mIL18 CAR T cells exhibited enhanced levels of IFN-γ secretion in the 
presence of EL4hCD19+ tumor cells (p = 0.0009) (Figure 5B). These endogenous T cells 
were negatively impacted in the presence of blocking MHC-I antibodies but not MHC-II 
blocking antibodies (Figure 5C), suggesting that broadening of the anti-tumor response was 
T cell receptor (TCR)/MHC-I restricted. To corroborate these results, we conducted similar 
experiments utilizing CAR− splenocytes derived from mice treated with Thy1.1-derived 
CAR T cells injected into EL4hCD19+ tumor-bearing syngeneic mice. Thy1.1-negative 
splenocytes were FACS sorted (Figure S6B), cocultured in vitro with either EL4hCD19+ or 
EL4hCD19− tumor cells, and assayed for IFN-γ cytokine production. CAR− splenocytes 
derived from mice treated with 19m28mz-mIL18 CAR-treated mice secreted increased 
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amounts of IFN-γ in both EL4hCD19+ (Figure 5D) and EL4hCD19− (Figure 5E) coculture 
experiments (p = 0.005 and p = 0.009, respectively). Taken together, these experiments 
demonstrate that 19m28mz-mIL18 CAR T cells are capable of recruiting endogenous anti-
tumor immune effector cells and broadening the anti-tumor response beyond the CAR target.
Next, to investigate the role of other endogenous immune cells and their potential 
contribution to long-term survival after IL-18 CAR therapy, we depleted either host 
macrophages or NK cells. Depletion of murine macrophages (Figure S7A) prior to 
inoculation with EL4hCD19+ tumor cells followed by treatment with 19m28mz-mIL18 
CAR T cells led to a significant decrease in long-term survival (p = 0.03) (Figure 5F). 
Clodronate alone did impact survival in tumor-bearing mice (Figure S7B). Interestingly, 
depletion of NK cells (Figure S7C) prior to 19m28mz-mIL18 CAR T cell inoculation did 
not interfere with long-term survival (Figure 5G). These results demonstrate that despite the 
fact that 19m28mz-mIL18 CAR T cells activate both macrophages and NK cells in the bone 
marrow, only macrophages display significant anti-tumor activity and act in combination 
with the CAR T cells to optimally eradicate tumor cells in vivo.
DISCUSSION
In this study, we demonstrate that CAR T cells further modified, or armored, to secrete the 
immune-modulatory IL-18 cytokine exhibit enhanced expansion, persistence, and anti-tumor 
cytotoxicity compared to T cells modified to express the tumor-targeted CAR alone. 
Furthermore, these armored CAR T cells, through targeted delivery of IL-18 to the tumor, 
modulate the EL4 tumor microenvironment, recruit, and activate endogenous anti-tumor 
immune effector cells, which in turn orchestrate an effective and comprehensive anti-tumor 
endogenous immune response, including broadening the anti-tumor response beyond the 
CAR target.
Based on current clinical trial studies in patients with B cell malignancies treated with 
CD19-targeted CAR T cells, limitations with respect to magnitude and durability of 
responses seem to correlate with in vivo CAR T cell expansion and persistence. 
Furthermore, relapses after initial responses correlate with CAR-targeted antigen escape 
variants. In the solid tumor setting, CAR T cell therapy efficacy is likely further limited by a 
highly immunosuppressive tumor microenvironment scaffolding the tumor (Brown et al., 
2016; Feng et al., 2017; Jackson et al., 2016; Louis et al., 2011; Wang et al., 2015). The 
utility of further engineering CAR T cells to secrete IL-18 is underscored by recent 
publications (Hu et al., 2017; Chmielewski and Abken, 2017). Hu and colleagues reported 
superior efficacy of IL-18-secreting CAR T cells in a xenograft model of CD19+ 
hematologic malignancies. Furthermore, they reported that this effect was mediated via 
autocrine stimulation of the IL-18 receptor. As the authors indicated, evaluation in 
immunodeficient NSG mice precluded analysis of the tumor microenvironment. In a more 
recent study, Chmielewski and Abken (2017) showed rejection of pancreatic cancer in a 
syngeneic mouse model using this approach. IL-18-enhanced CAR T cells promoted 
inflammatory changes in the solid tumor microenvironment by activating DCs, polarizing 
macrophages, and recruiting NK cells. Our studies recapitulate, bridge, and extend these 
findings, further enhancing our understanding of IL-18 armored CAR T cells. Consistent 
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with recently published data, our results demonstrate a substantial dependence on autocrine 
IL-18R-mediated stimulation of the CAR T cells.
Utilizing CyTOF analysis, we found that 19m28mz-mIL18 CAR T cells were not only 
capable of migration, and persistence in the bone marrow, but also induced endogenous CD8 
T cells, macrophages, and DCs toward a more effective anti-tumor phenotype. Enhanced 
survival of mice inoculated with high doses of a mixed population of hCD19+ and hCD19− 
tumor cells and treated with 19m28mz-mIL18 CAR T cells further suggest that these IL-18-
secreting CAR T cells effectively recruit and activate endogenous T cells responsible for 
clearing CD19− tumor cells. We tested this hypothesis via multiple approaches and found 
that 19m28mz-mIL18 CAR T cells are indeed stimulating endogenous T cells to recognize 
both antigen-positive and antigennegative tumor cells via MHC-I/TCR engagement. 
Collectively, these results are suggestive of broadening of the anti-tumor response resulting 
from engagement of endogenous tumor-targeting immune effector cells.
Next, we demonstrate the important role of IL-18-mediated macrophage phenotype switch 
via pharmacological depletion of macrophages in mice treated with 19m28mz-mIL18 CAR 
T cells. This is consistent with literature supporting the role of pro-inflammatory M1 
macrophages in suppressing tumorigenicity (Mantovani et al., 2002; Yuan et al., 2015). 
These results are not incompatible with data showing the importance of IL-18/IL-18R 
autocrine activity. Modulation of macrophages and the EL4 tumor microenvironment occurs 
as a secondary activity after expansion of IL-18-modified CARs. Lack of IL-18/IL-18R 
autocrine engagement limits this initial expansion, which leads to only modest levels of 
IL-18 in the TME. This explains why macrophage depletion only partially impacts efficacy, 
whereas IL-18 receptor deletion completely abrogates survival. In contrast, and somewhat 
unexpectedly, we found that despite IL-18-mediated enhanced recruitment of NK cells to the 
tumor site, depletion of NK cells had no apparent impact on treatment outcomes. This is not 
what we would have predicted based on our data and published reports by Chmielewski and 
Abken (2017). At this time, it is not clear whether this finding is related to the tumor model 
or whether this finding extends to other malignancies. This is a focus of ongoing studies.
Significantly, we have expanded our findings of IL-18 armored CAR T cells to the setting of 
MUC16ecto targeted CAR T cells in an ovarian cancertumor model. As noted, solid tumors 
express targeted antigens heterogeneously, making tumor escape a significant obstacle to 
CAR-mediated tumor eradication. Despite a known immunosuppressive tumor 
microenvironment in syngeneic ID8 tumor cells (Hart et al., 2011; Khan et al., 2015), we 
were able to show efficacy of IL-18 engineered CAR T cells in this difficult-to-treat model. 
The work presented here, taken together with the recently published data on IL-18 
augmented CAR T cells, further expand the application of this technology to a far broader 
spectrum of malignancies.
EXPERIMENTAL PROCEDURES
Generation of Retroviral Constructs
SFG-19m28mz-mIL18, SFG-19mDEL, SFG-19mDEL-mIL18 CAR T cell vectors were 
derived from SFG-19mz constructs. SFG-1928z and 1928z-hIL18 vectors were derived from 
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the 19z construct, as previously described (Brentjens et al., 2003; Pegram et al., 2012). 
4H11m28mz-mIL18 construct was derived from 4H11m28mz vector, as previously 
described (Chekmasova et al., 2010; Koneru et al., 2015). Both human and mouse IL-18 
genes (Integrated DNA Technologies [IDT]) were designed and modified to include an IL-2 
signal peptide and a self-cleaving 2a peptide (P2A).
T Cell Isolation and Gene Transfer
Murine T cells were isolated from splenocytes as previously described (Pegram et al., 2012). 
Murine CAR T cells were maintained in culture with RPMI in the presence of 100 IU/mL 
recombinant human IL-2 (Proleukin; Novartis, Basel, Switzerland), selected with Nylon 
Wool Fiber (Polysciences, Warrington, PA), and activatedwith CD3/CD28 beads, 
accordingto manufacturer’s instructions (Gibco, Thermo Fisher, Waltham, MA). Human T 
cells were derived from fresh blood-derived leukocyte concentrate (Leukopack) obtained 
from the New York Blood Center. Mononuclear cells were separated using density gradient 
centrifugation with Accu-prep (axis-Shield PoC AS, Oslo, Norway). T cells were isolated, 
activated, and expanded with 2 × 106/mL PHA (Sigma Aldrich, St. Louis, MO). T cells were 
cultured in RPMI 1640 in the presence of 100 IU/mL recombinant human IL-2 (Proleukin). 
Viable cells were enumerated using flow cytometry and counting beads (Ebioscience), 
following manufacturer’s protocol. Activated human and mouseT cells were 
retrovirallytransduced as previously described (Pegram et al., 2012, 2015). CAR expression 
was detected using Armenian hamster 12D11 antibody (anti-CD19 CAR) or an Alexa Fluor 
647-conjugated hamster antibody that specifically binds the 4H1128z CAR (Monoclonal 
Antibody Facility, Memorial Sloan Kettering Cancer Center).
Proliferation, In Vitro Cytolysis, and Exhaustion Analysis
Proliferation assays were performed by co-culturing 1928z and 1928z-P2A-hIl-18 CAR T 
cells with NALM6 tumor cells at a 1:1 ratio. CAR T cell expansion was calculated on days 7 
and 14, and cells were re-stimulated with NALM6 tumor cells on days 8 and 15. CAR T cell 
expansion was calculated using flow cytometry and counting beads (Ebioscience) according 
to manufacturer’s instructions. T cell cytotoxicitywas assessed by standard 51Cr release 
assays as previously described (Gong et al., 1999). Exhaustion analysis was performed in 
vitro by co-culturing CAR T cells with NALM6 tumor cell at 1:1 E:T ratio. CAR T cells 
were restimulated at days 6 and 12 with tumor cells, and analyses were performed at days 7 
and 14 forthe expression of PD-1, TIM-3, and LAG-3 markers using flow cytometry.
Mice and In Vivo Models
Syngeneic Mice Experiments—For CD19+ tumor cell experiments, syngeneic C57BL/6 
mCD19+/− hCD19+/− mice aged 6–8 weeks were inoculated with 1 × 106 EL4hCD19+ or 1 × 
106 EL4hCD19+ in combination with 1 × 106 EL4hCD19− tumor cells i.v. and treated with 
2.5 × 106 or 1.2 × 106 anti-hCD19 CART cells i.v. the following day, or 2.5 × 106 on day 7. 
C57BL/6 mCD19+/− hCD19+/− mice were used as both donor and recipient as previously 
described (Pegram et al., 2012). For delayed tumor model experiments, EL4hCD19+ tumor 
cells were inoculated on day 0 and CAR T cells were injected on day 7. Donor T cells were 
also isolated from IL-18R−/− mice (B6.129P2-Il18r1tm1Aki/J) (The Jackson Laboratory, 
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BarHarbor, ME). Micethatsurvived past day 150 were considered long-term survivors. 
Forsyngeneic ovarian mouse models, WT-C57BL/6 mice were inoculated with 1 × 107 ID8 
tumor cells on day 0 and treated with 2 × 106 anti-MUCecto16 CAR T cells either on day 24 
or 42 after tumor inoculation. For macrophage depletion studies, transgenic mice were 
treated with clodronate liposome or PBS liposome as control, 300 μL intraperitoneally (i.p.) 
on days −2, 0, 2, and 6. For NK cell depletion studies, transgenic mice were treated with 
NK1.1 antibody (BioxCell, West Lebanon, NH) or anti-IgG2a (BioxCell) as control, 100 μg 
i.p. on days −2, 0, 2, and 6. Sample sizes were chosen based on estimates from pilot 
experiments and previously published results to power appropriately.
Xenograft Mice Experiments—Fox Chase CB17 (CB17.Cg-PrkdcscidLystbg-J/Crl, 
SCID-Beige mice) (Charles River Laboratories, Wilmington, MA) aged 6–8 weeks were i.v. 
inoculated with 1 × 106 NALM6-GFP+/Luc+ tumor cells on day 0 and on day 1, treated with 
one systemic infusion of 5 × 106 CAR+ human blood-derived T cells. Bioluminescent 
imaging was achieved using the Caliper IVIS imaging system and analyzed with Living 
Image 4.0 software (PerkinElmer, Waltham, MA). Tumor-bearing mice were injected 
intraperitoneally with D-Luciferin (Goldbio Technology, St. Louis, MO) (150 mg/kg) and 
after 10 min were imaged under isoflurane anesthesia. Image acquisition was achieved using 
a 25-cm field of view, medium binning level, and 60-s exposure time.
All mice were monitored for survival and were euthanized when showing signs of distress. 
All murine studies were done in the context of a Memorial Sloan Kettering Cancer Center 
Institutional Animal Care and Use Committee approved protocol (00-05-065).
PCR Analysis
Bone marrow samples were collected on days 35, 80, 120, and 150 from mice injected with 
19m28mz-mIL18 CAR T cells. Cells were lysed with TRIzol (Life Technologies, Carlsbad, 
CA), followed by RNA extraction using extraction kit (Life Technologies). RNA samples 
were converted to cDNA using first-strand cDNA synthesis kit (New England Biolabs, 
Ipswich, MA) and proceeded to PCR analysis using an Eppendorf cycler (Eppendorf, 
Hauppauge, NY) and primers specific to anti-CD19 CAR T cells (SFGFwd, 
agaacctagaacctcgctggaaag, and mZetaRev, gtgcattgtatacgccttcctgggggt). Estimated final 
PCR product size was 1,450 bp.
Mass Cytometry (CyTOF)
Mass Cytometry Antibodies—Asummary of all mass cytometry antibodies, reporter 
isotopes, and concentrations used for analysis can be found in Table S1. Primary conjugates 
of mass cytometry antibodies were prepared using the MaxPAR antibody conjugation kit 
(Fluidigm) according to the manufacturer’s recommended protocol. Mass-tag cellular 
barcoding was performed as previously described (Zunder et al., 2015). Briefly, 1 × 106 cells 
from each animal were barcoded with distinct combinations of stable Pd isotopes chelated 
by isothiocyanobenzyl-EDTA in 0.02% saponin in PBS. Samples from any given tissue from 
one mouse per treatment group were barcoded together, with at least three biological 
replicates per treatment group across different plates.
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Scaffold Map Generation
Total live leukocytes (excluding erythrocytes) were used for all analyses. Scaffold maps 
were then generated as previously reported (Spitzer et al., 2015). Briefly, we chose the bone 
marrow data from mice receiving wildtype CAR T cells to spatialize the initial Scaffold 
map. A graph was constructed by first connecting together the nodes representing the 
manually gated landmark populations and then connecting to them the nodes representing 
the cell clusters as well as connecting the clusters to one another. Each node is associated 
with a vector containing the median marker values of the cells in the cluster (unsupervised 
nodes) or gated populations (landmark nodes). Edge weights were defined as the cosine 
similarity between these vectors after comparing the results from the implementation of 
several distance metrics. Edges of low weight were filtered out. We experimented with 
different threshold values for the weights, and we found values of 0.8 for the initial subgraph 
of landmark nodes, and 0.7 for the complete graph to produce satisfying results.
IFN-γ ELISPOT Assay
The Mouse IFN-gamma ELISPOT set (Invitrogen) was used for an IFN-γ ELISPOT assay. 
C57BL/6 syngeneic mice splenocytes were transduced with various CAR constructs and 
injected on day 1 i.v. into EL4 tumorbearing mice. On day 7, splenocytes were collected and 
sorted for CD3+ CAR− population. 1 × 105 splenocytes were cocultured with 1 × 105 
EL4hCD19+ and EL4hCD19- tumor cells. For MHC blocking experiments, MHC-I (Thermo 
Fisher Scientific, catalog #MA1-81644) or MHC-II (Thermo Fisher Scientific, catalog 
#16-5321-81) blocking antibodies were added to the T cell/tumor coculture at 10 ng/mL 
concentrations for the duration of the experiment. The experiments were conducted 
according to manufacturer’s instructions. The number of spots was evaluated in blinded 
fashion by ZellNet Consulting (Fort Lee, NJ) with a KS ELISPOT Reader System 
(Thornwood, NY), Software Version KS ELISPOT 4.9. Parameters were adjusted following 
the International Harmonization Guidelines for ELISPOT plate evaluation.
NanoString Technology Gene Expression Analysis
CAR T cells were co-cultured with tumor cells at a 1:1 ratio and flow sorted after co-
culturing for 1 day or 8 days with a second tumor stimulation on day 7 of culture. Total RNA 
was extracted with Ambion RNA extraction kit (Life Technologies) according to 
manufacturer’s instructions. RNA expression levels of 770 genes was detected using 
nanoString array (nCounter, Gene expression code set, PanCancer Immune Profiling Panel) 
and analyzed using nSolver Analysis system. Only statistically significant genes are shown 
(p < 0.05). The entire dataset has been deposited in the Gene Expression Omnibus (GEO) 
under accession number GEO: GSE97343.
Statistical Analysis
Survival curves were analyzed using Mantel-Cox (log-rank) test and other analysis were 
performed using two-tailed t test (p value <0.05 considered as significant). All calculations 
were performed using Prism 7 (GraphPad) software. Data represent means ± SEM.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• IL-18-secreting CAR T cells enhance anti-tumor efficacy via IL-18 autocrine 
stimulation
• IL-18-secreting CAR T cells favorably alter EL4 tumor microenvironment
• IL-18-secreting CAR T cells enhance the anti-tumor response of endogenous 
T cells
• IL-18-secreting CAR T cells are efficacious in syngeneic models without 
preconditioning
Avanzi et al. Page 16
Cell Rep. Author manuscript; available in PMC 2018 June 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Human 1928z-hIL18 CAR T Cells Enhance Survival of CD19+ Tumor-Bearing Scid-
Beige Xenograft Mice
(A) Representation of the human CAR constructs.
(B) In vitro cytokine secretion of IL-18, IFN-γ, and IL-2 after coculture with NALM6 tumor 
cells (E:T, 1:1).
(C) In vitro proliferation assay with 1928z and 1928z-hIL18 CAR T cells co-cultured with 
NALM6 tumor cells (E:T 1:1). CAR T cells were stimulated on day 0 and day 7.
(D) In vitro cytotoxicity utilizing standard 4-hr 51Cr release assay comparing 1928z and 
1928z-hIL18 CAR T cells.
(E) In vitro cytotoxicity over the course of 72 hr. 1928z versus 1928z-hIL18, *p < 0.05.
(F and G) Statistically significant (p < 0.05) differential gene expression between 1928z and 
1928z-hIL18 CAR T cells in vitro at day 1 (F) and day 8 after NALM6 tumor stimulation 
(G).
(H) Survival curve comparing 1928z and 1928z-hIL18 CAR T cells in a NALM6-GFP+/Luc
+
-tumor bearing xenograft Scid-Beige mouse model.
(I) Bioluminescence imaging comparing 1928z and 1928z-hIL18 CAR T cells in Scid-Beige 
mice inoculated with NALM6-GFP+/Luc+ tumor cells.
Survival curves analyses were performed using Mantel-Cox test. Other analyses were 
determined with Student’s t test. All results were pooled from at least two independent 
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experiments. Data in (B)–(E) represent means ± SEM. *p < 0.05, **p < 0.01, and ***p < 
0.001 for indicated comparison. ns, non-significant.
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Figure 2. Murine 19m28mz-mIL18 CAR T Cells Enhance Long-Term Survival of CD19+ Tumor-
Bearing Syngeneic Mice
(A) Representation of murine CAR T cell constructs.
(B) In vitro murine IL-18 secretion after stimulation with EL4hCD19+ tumor cells (E:T, 
1:1).
(C and D) Survival of EL4hCD19+ tumor-bearing mice treated on day 1 with (C) full dose 
(2.5 × 106) or (D) half dose (1.2 × 106) of CAR T cells/mouse.
(E) Survival of mice treated with 19m28mz-mIL18 CAR T cells in a delayed tumor model. 
Mice were inoculated with 1 × 106 EL4hCD19+ tumor cells on day 0 and treated with 2.5 × 
106 CAR T cells on day 7. Dashed line indicates day of CAR T cell infusion.
(F) Survival of mice inoculated with 1 × 106 EL4hCD19+ tumorcellson day0, treated with 
2.5 × 106 19m28mz-mIL18 CAR T cells on day 1, and then rechallenged with 1 × 106 
EL4hCD19+ tumor cells on day 40. Control untreated mice were inoculated with 1 × 106 
EL4hCD19+ tumor cells on either day 0 or day 40.
Data in (B) represent means ± SEM. Survival curves analyseswere made using Mantel-
Coxtest. *p < 0.05, **p < 0.01, and ***p < 0.001 for indicated comparison. All results were 
pooled from at least two independent experiments.
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Figure 3. 19m28mz-mIL18 CAR T Cells Display Enhanced Expansion and Persistence and 
Depend on Autocrine IL-18 Signaling
(A) CAR T cells from peripheral blood quantified by flow cytometry.
(B) Peripheral blood B cell aplasia quantified via flow cytometry.
(C) Bone marrow PCR analysis of mice treated with 19m28mz-mIL18 CAR T cells.
(D) Serum cytokine quantification on day 7, comparing 19m28mz and 19m28mz-mIL18 
CAR T cells.
(E) Survival of EL4hCD19+ tumor-bearing mice treated with 19mz-mIL18 or 19m28mz-
mIL18.
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(F) Quantification of day 7 peripheral blood CAR T cell in vivo.
(G) Day 7, 30, and 60 peripheral blood B cell aplasia.
(H) Survival of EL4hCD19+ tumor-bearing mice treated with IL18R-KO 19m28mz-mIL18 
or WT 19m28mz-mIL18 CAR T cells.
(I) Day 7 peripheral blood CAR T cell quantification.
(J) Day 7 peripheral blood B cell aplasia.
(K) Day 7 serum IFN-γ quantification.
Survival curves comparisons were made using Mantel-Cox test. All results were pooled 
from at least two independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 for 
indicated comparison. ns, non-significant.
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Figure 4. 19m28mz-mIL18 CAR T Cells Modulate the Tumor Microenvironment and Activate 
Endogenous Immune Cells
(A) Detection of CAR T cells in the bone marrow.
(B) Statistical scaffold map of the bone marrow. Size of unsupervised clusters denotes the 
relative number of cells in that grouping. Nodes in red denote landmark populations, defined 
manually. Blue nodes reflect unsupervised clusters of cells from raw dataset. Log2 fold 
change of manually gated populations comparing bone marrow of mice treated with 
19m28mz or 19m28mz-mIL18 CAR T cells with statistically significant differences noted (p 
< 0.05).
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(C) Detection of endogenous CD8 non-CAR T cells and CD8 19m28mz-mIL18 CART cells 
in the bone marrow of mice treated with 19m28mz-mIL18 CAR T cells.
(D–F) Phenotypic analysis of bone marrow endogenous cells of mice treated with 19m28mz 
or 19m28mz-mIL18 CAR T cells: (D) endogenous CD8 T cells, (E) macrophages, and (F) 
dendritic cells.
(G) Statistical Scaffold map of the bone marrow comparing the phenotype of endogenous 
non-CAR T cells and 19m28mz-mIL18 CART cells in mice treated with 19m28mz-mIL18 
CAR T cells.
Results are pooled data of two independent experiments. Adjustment by the Benjamini-
Hochberg procedure for multiple testing. Data in (B) and (D)–(F) represent means ± SD. *p 
< 0.05, **p < 0.01, and ***p < 0.001 for indicated comparison. ns, non-significant.
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Figure 5. IL-18-Secreting CAR T Cells Engage Endogenous Anti-tumor Immune Effector Cells
(A) Survival curve of mice inoculated with both 1 × 106 EL4hCD19+ and 1 × 106 
EL4hCD19− tumor cells and treated on D1 with 19m28mz or 19m28mz-mIL18 CAR T 
cells.
(B) IFN-γ ELISPOT results comparing CD3+ CAR-negative splenocytes from mice treated 
with 19m28mz, 19m28mz-mIL18 CAR T cells, or naive mice after coculture with 
EL4hCD19+ tumor cells.
(C) IFN-γ ELISPOT comparing CD3+ CAR-negative splenocytes from mice treated with 
19m28mz, 19m28mz-mIL18 CAR T cells, or naive mice after coculture with EL4hCD19+ 
tumor cells with/without MHC-I or MHC-II blocking antibodies.
(D) IFN-γ cytokine quantification comparing CAR-negative splenocytes after 24 hr of 
exposure to EL4hCD19+ tumor cells (1:1 E:T ratio).
(E) IFN-γ cytokine quantification comparing CAR-negative splenocytes after 24 hr of 
exposure to EL4hCD19− tumor cells (1:1 E:T ratio).
(F) Survival of mice treated with 19m28mz-mIL18 CAR T cells with or without macrophage 
depletion.
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(G) Survival of mice treated with 19m28mz-mIL18 CAR T cells with or without NK cell 
depletion.
Survival curves analyses performed using Mantel-Cox test. Data in (B)–(E) represent means 
± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 for indicated comparison. ns, non-
significant. All results were pooled from at least two independent experiments.
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